Clinic Roundup
DBV Technologies, of Bagneux, France, said the first patient has been enrolled in the VIPES Phase IIb study of Viaskin, an epicutaneous immunotherapy approach to desensitizing against peanut allergy via a skin patch. A total of 220 peanut-allergic subjects, ranging in age from 6 to 55, with a history of immediate hypersensitive reaction to peanut protein, will be enrolled in the study.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.